Company intelligence / Profile preview
MabSwitch
San Carlos, California, United Statesmabswitch.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MabSwitch has developed a proprietary platform, UNASMA™, enabling ON/OFF control switches for antibodies to regulate their binding affinity. This technology aims to improve the safety and utility of therapeutic antibodies by allowing reversible modulation of their activity. The company has received innovation awards but does not yet report clinical results or advanced-stage programs.
- Therapeutic areas
- Infectious DiseasesImmunologyOncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
California Life Sciences/Johnson & Johnson Innovation/AbbVie/5AM Ventures via CLS Inspire QuickFire Challenge award partnership/support—not formal commercial partnerships but significant ecosystem engagement.
Beyond the preview
Go deeper on MabSwitch.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MabSwitch.